Efficacy and safety of imatinib in patients with COVID-19: a systematic review and meta-analysis.

IF 1.9 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Wiener Klinische Wochenschrift Pub Date : 2025-06-19 DOI:10.1007/s00508-025-02552-4

Le Li, Chengxiao Zhao, Siyuan Hou

{"title":"Efficacy and safety of imatinib in patients with COVID-19: a systematic review and meta-analysis.","authors":"Le Li, Chengxiao Zhao, Siyuan Hou","doi":"10.1007/s00508-025-02552-4","DOIUrl":null,"url":null,"abstract":"Objective: To inform treatment decisions in clinical practice, we conducted a meta-analysis to evaluate the efficacy and safety of imatinib in patients with COVID-19.Methods: A comprehensive systematic search was conducted across multiple electronic databases to identify relevant randomized controlled trials (RCTs) comparing imatinib with placebo in patients with COVID-19. A meta-analysis was performed using Review Manager software version 5.3 and followed the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses.Results: The analysis included 4 studies with a total of 717 patients. The risk ratio (RR) for 28-day mortality in the imatinib group compared to the placebo group was 0.79 (95% confidence interval. CI 0.51-1.21; p = 0.28). There were no statistically significant differences in the duration of oxygen supplementation (MD = -0.13, 95% CI -2.57-2.31; p = 0.92) or the number of ventilator-free days (MD = 4.71, 95% CI -6.97-16.38; p = 0.43). Imatinib treatment did not significantly reduce the duration of hospital or intensive care unit (ICU) stay. Additionally, there was no significant difference between imatinib and placebo in the risk of any adverse events (AEs) or serious AEs.Conclusion: Imatinib did not significantly improve clinical outcomes in patients with COVID-19. Future research should consider subgroup analyses based on the biological heterogeneity of COVID-19-associated acute respiratory distress syndrome (ARDS) or the concurrent use of interleukin 6 (IL-6) receptor inhibitors to identify patient populations that may benefit from imatinib treatment.","PeriodicalId":23861,"journal":{"name":"Wiener Klinische Wochenschrift","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Wiener Klinische Wochenschrift","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00508-025-02552-4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To inform treatment decisions in clinical practice, we conducted a meta-analysis to evaluate the efficacy and safety of imatinib in patients with COVID-19.

Methods: A comprehensive systematic search was conducted across multiple electronic databases to identify relevant randomized controlled trials (RCTs) comparing imatinib with placebo in patients with COVID-19. A meta-analysis was performed using Review Manager software version 5.3 and followed the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses.

Results: The analysis included 4 studies with a total of 717 patients. The risk ratio (RR) for 28-day mortality in the imatinib group compared to the placebo group was 0.79 (95% confidence interval. CI 0.51-1.21; p = 0.28). There were no statistically significant differences in the duration of oxygen supplementation (MD = -0.13, 95% CI -2.57-2.31; p = 0.92) or the number of ventilator-free days (MD = 4.71, 95% CI -6.97-16.38; p = 0.43). Imatinib treatment did not significantly reduce the duration of hospital or intensive care unit (ICU) stay. Additionally, there was no significant difference between imatinib and placebo in the risk of any adverse events (AEs) or serious AEs.

Conclusion: Imatinib did not significantly improve clinical outcomes in patients with COVID-19. Future research should consider subgroup analyses based on the biological heterogeneity of COVID-19-associated acute respiratory distress syndrome (ARDS) or the concurrent use of interleukin 6 (IL-6) receptor inhibitors to identify patient populations that may benefit from imatinib treatment.

查看原文本刊更多论文

伊马替尼治疗COVID-19患者的疗效和安全性：系统回顾和荟萃分析

目的：为指导临床治疗决策，我们开展了一项meta分析，评估伊马替尼治疗COVID-19患者的疗效和安全性。方法：在多个电子数据库中进行全面的系统检索，以确定比较伊马替尼与安慰剂治疗COVID-19患者的相关随机对照试验（rct）。采用Review Manager软件5.3版进行meta分析，并遵循系统评价和meta分析首选报告项目的指导方针。结果：纳入4项研究，共717例患者。与安慰剂组相比，伊马替尼组28天死亡率的风险比（RR）为0.79（95%置信区间）。可信区间0.51 - -1.21; p = 0.28)。两组患者补氧时间差异无统计学意义(MD = -0.13,95% CI -2.57-2.31；p = 0.92)或无呼吸机天数(MD = 4.71,95% CI -6.97-16.38； p = 0.43)。伊马替尼治疗并没有显著减少住院或重症监护病房（ICU）的住院时间。此外，在任何不良事件（ae）或严重ae的风险方面，伊马替尼和安慰剂之间没有显著差异。结论：伊马替尼对COVID-19患者的临床结局无显著改善作用。未来的研究应考虑基于covid -19相关急性呼吸窘迫综合征（ARDS）的生物学异质性或同时使用白细胞介素6 （IL-6）受体抑制剂的亚组分析，以确定可能从伊马替尼治疗中受益的患者群体。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Wiener Klinische Wochenschrift 医学-医学：内科

CiteScore

4.70

自引率

3.80%

发文量

110

审稿时长

4-8 weeks

期刊介绍： The Wiener klinische Wochenschrift - The Central European Journal of Medicine - is an international scientific medical journal covering the entire spectrum of clinical medicine and related areas such as ethics in medicine, public health and the history of medicine. In addition to original articles, the Journal features editorials and leading articles on newly emerging topics, review articles, case reports and a broad range of special articles. Experimental material will be considered for publication if it is directly relevant to clinical medicine. The number of international contributions has been steadily increasing. Consequently, the international reputation of the journal has grown in the past several years. Founded in 1888, the Wiener klinische Wochenschrift - The Central European Journal of Medicine - is certainly one of the most prestigious medical journals in the world and takes pride in having been the first publisher of landmarks in medicine.